Zoetis (ZTS) Stock Forecast & Price Target

Zoetis logo
$79.09 -1.70 (-2.10%)
Closing price 11/20/2026 03:59 PM Eastern
Extended Trading
$78.67 -0.42 (-0.53%)
As of 11/20/2026 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zoetis - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
1
Hold
11
Buy
8

Based on 20 Wall Street analysts who have issued ratings for Zoetis in the last 12 months, the stock has a consensus rating of "Hold." Out of the 20 analysts, 1 has given a sell rating, 11 have given a hold rating, and 8 have given a buy rating for ZTS.

Consensus Price Target

$101.25
28.02% Upside
According to the 20 analysts' twelve-month price targets for Zoetis, the average price target is $101.25. The highest price target for ZTS is $155.00, while the lowest price target for ZTS is $74.00. The average price target represents a forecasted upside of 28.02% from the current price of $79.09.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for ZTS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Zoetis and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ZTS Analyst Ratings Over Time

TypeCurrent Forecast
11/21/25 to 11/21/26
1 Month Ago
10/22/25 to 10/22/26
3 Months Ago
8/23/25 to 8/23/26
1 Year Ago
11/21/24 to 11/21/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
9 Buy rating(s)
10 Buy rating(s)
6 Buy rating(s)
Hold
11 Hold rating(s)
11 Hold rating(s)
10 Hold rating(s)
5 Hold rating(s)
Sell
1 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$101.25$104.59$113.13$178.89
Forecasted Upside28.02% Upside27.69% Upside45.55% Upside46.56% Upside
Consensus RatingHoldHoldHoldModerate Buy

ZTS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ZTS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Zoetis Stock vs. The Competition

TypeZoetisHealthcare CompaniesBroader Market
Consensus Rating Score
2.35
2.32
2.52
Consensus RatingHoldHoldModerate Buy
Predicted Upside28.02% Upside122.27% Upside22.06% Upside
News Sentiment Rating
Neutral News

See Recent ZTS News
Neutral News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
11/6/2026
Keith Devas
Keith Devas
Not Rated
Boost Target$83.00 ➝ $85.00+7.77%
10/30/2026
BTIG Research logo
BTIG Research
3 of 5 stars
Mark Massaro
Mark Massaro
4 of 5 stars
Dropped CoverageBuy$200.00 ➝ $160.00+100.83%
10/29/2026
Weiss Ratings logo
Weiss Ratings
2 of 5 stars
 UpgradeSell (D) ➝ Sell (D+)
10/29/2026Lower TargetOverweight$85.00 ➝ $82.00+4.82%
10/27/2026Boost TargetNeutral$80.00 ➝ $85.00+7.46%
10/26/2026 UpgradeStrong Sell ➝ Hold
10/16/2026Initiated CoverageBuy ➝ Neutral$74.00-5.94%
8/25/2026Lower TargetBuy$104.00 ➝ $94.00+21.87%
8/25/2026 Set Target$94.00+21.87%
8/20/2026Lower TargetHold$85.00 ➝ $80.00+4.19%
8/11/2026Lower TargetBuy$112.00 ➝ $96.00+27.60%
8/11/2026Lower TargetOutperform$146.00 ➝ $110.00+46.54%
8/10/2026Lower TargetNeutral$90.00 ➝ $80.00+7.42%
8/7/2026Lower TargetOverweight$130.00 ➝ $115.00+58.36%
8/6/2026DowngradeOutperform ➝ Market Perform
7/13/2026 Lower TargetMarket Perform$95.00 ➝ $80.00+1.44%
7/6/2026Lower TargetBuy$140.00 ➝ $95.00+26.18%
7/1/2026Lower TargetEqual Weight$136.00 ➝ $85.00+18.25%
5/27/2026DowngradeBuy ➝ Hold
5/8/2026 DowngradeBuy ➝ Hold
2/17/2026 Lower TargetBuy$165.00 ➝ $155.00+96.73%
2/13/2026Boost TargetNeutral$135.00 ➝ $140.00+11.48%
11/20/2025Initiated CoverageSector Weight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 02:14 AM ET.


Should I Buy Zoetis Stock? ZTS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, November 15, 2026. Please send any questions or comments about these Zoetis pros and cons to contact@marketbeat.com.

Zoetis
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Zoetis Inc.:

  • Zoetis Inc. recently secured a USDA license for Cytopoint Plus, a next-generation monoclonal antibody that provides 75 days of allergic itch relief in dogs with a single injection. This product innovation is significant because it offers a longer interval between treatments compared to previous options, which can improve customer convenience and potentially drive higher sales volumes in the companion animal segment.
  • The company demonstrated strong earnings resilience by beating analyst expectations in its most recent quarter, reporting earnings per share of $1.75 against a consensus estimate of $1.51. This beat of $0.24 per share indicates that Zoetis Inc. is effectively managing its costs and operational efficiency, allowing it to deliver higher profits than the market anticipated despite broader industry headwinds.
  • Zoetis Inc. offers an attractive dividend yield of 2.53%, providing investors with a steady income stream. With a dividend payout ratio of approximately 36%, the company retains a significant portion of its earnings for reinvestment, suggesting that the dividend is sustainable and supported by the company's strong cash flow generation.
  • The stock currently trades at $83.65, which is significantly below its 52-week high of $132.49. This price level may present a value opportunity for investors, as the stock has experienced a substantial correction from its peak, potentially offering an entry point before a potential recovery driven by new product launches and improved market conditions.
  • Zoetis Inc. has a low beta of 0.67, indicating that the stock is less volatile than the overall market. This characteristic can be beneficial for investors seeking to reduce portfolio risk, as the stock tends to experience smaller price swings in response to market fluctuations, providing a more stable investment profile.

Zoetis
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Zoetis Inc. for these reasons:

  • Zoetis Inc. is facing persistent pressure in its companion animal business, with U.S. companion animal sales falling by 8% in the most recent quarter. This decline is attributed to competitive pressures and weaker veterinary visits, which directly impacts the company's revenue growth and profitability in a key market segment.
  • The company's revenue has shown signs of weakness, with the most recent quarter reporting a year-over-year revenue decline of 1.3%. This negative growth trend suggests that Zoetis Inc. is struggling to expand its top line, which could limit its ability to invest in new products and maintain its market position.
  • Wall Street analysts have a consensus rating of "Hold" for Zoetis Inc., with a consensus price target of $98.07. This rating indicates that analysts believe the stock is fairly valued and do not see significant upside potential in the near term, which may limit the stock's price appreciation.
  • Zoetis Inc. has a high debt-to-equity ratio of 2.51, indicating that the company relies heavily on debt financing. This high leverage can increase financial risk, especially in a rising interest rate environment, as it may lead to higher interest expenses and reduced financial flexibility.
  • The stock has experienced a significant decline from its 52-week high of $132.49 to its current price of $83.65. This substantial drop reflects negative market sentiment and potential concerns about the company's future performance, which may deter investors from buying the stock.

ZTS Forecast - Frequently Asked Questions

According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Zoetis is $101.25, with a high forecast of $155.00 and a low forecast of $74.00.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last twelve months. There is currently 1 sell rating, 11 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ZTS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZTS, but not buy additional shares or sell existing shares.

According to analysts, Zoetis's stock has a predicted upside of 28.02% based on their 12-month stock forecasts.

Over the previous 90 days, Zoetis's stock had 2 upgrades and 1 downgrade by analysts.

Analysts like Zoetis more than other "healthcare" companies. The consensus rating score for Zoetis is 2.35 while the average consensus rating score for "healthcare" companies is 2.32. Learn more on how ZTS compares to other companies.


MarketBeat monitors more than a dozen sources for Zoetis analyst ratings, with the most recent rating issued on 11/6/2026.
From Our Partners